Outlook Therapeutics, Inc. Common Stock
Here’s whether Outlook Therapeutics, Inc. Common Stock (OTLK) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+27.47% over 10 days); RSI 49 — healthy momentum range; 3-month momentum positive (+345.9%). Concerns: weak 1-year return of -29.8%. Currently 58.5% off its 52-week high. Score: +5/7.
OTLK is in a confirmed uptrend, trading above both its 50-day ($1.13) and 200-day ($0.94) moving averages. An RSI of 49.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -29.8% compares to +16.5% for SPY (trailed the market by 46.2%). The current 58.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.